<DOC>
	<DOCNO>NCT01949610</DOCNO>
	<brief_summary>The purpose study evaluate absorption , metabolic pathway ( series metabolic reaction ) excretion JNJ26489112 healthy male adult participant administration single oral dose 1000 mg 14C-JNJ26489112 .</brief_summary>
	<brief_title>A Study Evaluate Absorption , Metabolism , Excretion 14C-JNJ26489112 Healthy Male Participants</brief_title>
	<detailed_description>This single-dose , 1-arm ( group ) , open-label study ( people know identity intervention ) healthy adult male participant . On Day 1 , complete 10-hour overnight fast , participant receive single oral dose 14C-JNJ-26489112 1,000 mg 10-mL suspension . Participants recruit 2 cohort . The 6 participant first cohort dose error dose less 1000 mg . So , additional cohort 4 participant enrol receive single oral dose 1000 mg 14C-JNJ 26489112 . Total 10 participant receive study medication . Safety assess monitor vital sign , physical examination , electrocardiogram , clinical laboratory test throughout study . The total duration study participant approximately 5 week ( include 3 week screen 11 15 day study ) 1 additional week participant excrete 14C-JNJ26489112 slowly .</detailed_description>
	<criteria>Signed informed consent document indicate understand purpose procedure require study , willing participate study , willing adhere prohibition restriction specify protocol Had consistent bowel movement habit ( approximately per day ) within 30 day dose Blood pressure ( participant supine 5 minute ) 90 140 mmHg systolic , inclusive , high 90 mmHg diastolic A 12lead electrocardiogram consistent normal cardiac conduction function Exposure radiation professional medical reason exception 2 standard diagnostic radiograph ( eg , dental Xrays , plain chest Xray ) participation investigational study involve radioactivity within 1 year study drug administration Day 1 History current clinically significant medical illness include cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection Clinically significant abnormal value hematology , clinical chemistry urinalysis screen admission study center Clinically significant abnormal physical examination , vital sign 12lead electrocardiogram screening admission study center Clinically significant ocular deficit , include retinal disorder</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Healthy Participants</keyword>
	<keyword>JNJ26489112</keyword>
	<keyword>14C-JNJ26489112</keyword>
	<keyword>Absorption</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Excretion</keyword>
</DOC>